Terns Pharmaceuticals, Inc.
NASDAQ:TERN
4.66 (USD) • At close February 5, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 1 | 0 | 0 | 0 |
| Cost of Revenue
| 0.881 | 1.032 | 0.512 | 0.394 | 0.195 | 0.065 |
| Gross Profit
| -0.881 | -1.032 | 0.488 | -0.394 | -0.195 | -0.065 |
| Gross Profit Ratio
| 0 | 0 | 0.488 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 63.497 | 39.617 | 31.311 | 28.029 | 61.534 | 14.554 |
| General & Administrative Expenses
| 39.061 | 22.412 | 19.549 | 8.996 | 8.663 | 3.901 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 39.061 | 22.412 | 19.549 | 8.996 | 8.663 | 3.901 |
| Other Expenses
| 0 | -0.068 | 0.04 | -2.788 | 0.154 | 0.038 |
| Operating Expenses
| 102.558 | 62.029 | 50.86 | 37.025 | 70.197 | 18.455 |
| Operating Income
| -102.558 | -62.029 | -49.86 | -37.025 | -70.197 | -18.455 |
| Operating Income Ratio
| 0 | 0 | -49.86 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 12.587 | 2.042 | 0.21 | -2.733 | 1.358 | 0.37 |
| Income Before Tax
| -89.971 | -59.987 | -49.65 | -39.758 | -68.839 | -18.085 |
| Income Before Tax Ratio
| 0 | 0 | -49.65 | 0 | 0 | 0 |
| Income Tax Expense
| 0.239 | 0.358 | 0.508 | 0.813 | -0.02 | -0.067 |
| Net Income
| -90.21 | -60.345 | -50.158 | -40.571 | -68.819 | -17.711 |
| Net Income Ratio
| 0 | 0 | -50.158 | 0 | 0 | 0 |
| EPS
| -1.27 | -1.67 | -1.98 | -1.61 | -2.74 | -0.74 |
| EPS Diluted
| -1.27 | -1.67 | -1.98 | -1.61 | -2.74 | -0.74 |
| EBITDA
| -102.266 | -58.955 | -49.348 | -36.631 | -35.002 | -18.39 |
| EBITDA Ratio
| 0 | 0 | -49.86 | 0 | 0 | 0 |